Every Form 4 that Allarity Therapeutics, Inc. (ALLR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALLR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALLR filings page.
Jensen Thomas reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics CEO Thomas Jensen received an equity grant of 200,000 shares of common stock as a compensation award. These shares are in the form of restricted stock units granted under the company’s Amended and Restated 2021 Equity Incentive Plan and were awarded at no cash cost per share.
The RSUs will vest in three equal annual installments on the first, second, and third anniversaries of the January 28, 2026 grant date, if he continues his relationship with the company through each vesting date. After this grant, Jensen holds 596,734 common shares directly.
Allarity Therapeutics director Jesper Hoeiland was granted equity compensation. The Form 4 reports an acquisition of 25,000 shares of Common Stock at a stated price of $0.00 per share, bringing his direct holdings to 25,000 shares after the transaction.
According to a footnote, these shares reflect restricted stock units granted pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, which vested in full on the grant date. This filing reflects a compensation-related award rather than an open-market trade.
McLaughlin Gerald W. reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. director Gerald W. McLaughlin received a grant of 45,000 shares of common stock in the form of restricted stock units on January 28, 2026. These RSUs vested in full on the grant date, bringing his directly held position to 70,000 shares after the award.
Graff Jeremy R. reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. reported that officer Jeremy R. Graff received a grant of 133,333 shares of common stock in the form of restricted stock units on January 28, 2026. The award was granted at a stated price of $0.00 per share as equity compensation.
The RSUs were issued under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan and will vest in three equal installments on the first, second, and third anniversaries of the grant date, as long as Graff maintains a continued relationship with the company. Following this grant, he directly holds 381,644 shares of common stock.
Ervin Jeffrey S reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. reported that its CFO, Jeffrey S. Ervin, received a grant of 150,000 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he holds 150,000 shares directly.
The RSUs were granted on January 28, 2026 under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan. They will vest in equal one-third installments on the first, second, and third anniversaries of the grant date, if he continues his relationship with the company through each vesting date.
Allarity Therapeutics, Inc. reported an equity award to senior executive Jeremy R. Graff, its President and Chief Development Officer. On January 7, 2026, Graff received 133,333 shares of common stock in the form of restricted stock units at a price of $0 per share under the company’s Amended and Restated 2021 Equity Incentive Plan. These RSUs will vest in three equal one-third installments on the first, second, and third anniversaries of the grant date, conditioned on his continued relationship with the company. Following this award, Graff beneficially owns 381,644 shares of Allarity Therapeutics common stock, held directly.
Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc. (ALLR), reported transactions dated 09/30/2025. 39,494 restricted stock units vested and were reported as acquired, and 14,613 shares were disposed of at $1.58 per share, leaving 24,881 shares owned directly after the transactions. The filing also shows 223,430 restricted stock units/derivative securities beneficially owned following the reported transactions. The RSUs convert one-for-one to common stock and stem from grants of 118,483 RSUs on 09/30/2024 and 144,441 RSUs on 01/22/2025, each vesting in three equal annual installments beginning on the first anniversary of the respective grant dates.